Literature DB >> 9580606

Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides.

D E Brenneman1, J Hauser, E Neale, S Rubinraut, M Fridkin, A Davidson, I Gozes.   

Abstract

Activity-dependent neurotrophic factor (ADNF) is a glia-derived protein that is neuroprotective at femtomolar concentrations. A 14-amino acid peptide of ADNF (ADNF-14) has been reported that protects cultured neurons from multiple neurotoxins. Structure-activity relationships of peptides related to ADNF-14 now have been determined. A 9-amino acid core peptide (ADNF-9) has been identified that has greater potency and a broader effective concentration range (10(-16) to 10(-13) M) than ADNF or ADNF-14 in preventing cell death associated with tetrodotoxin treatment of cerebral cortical cultures. Deletions or conservative amino acid substitutions to ADNF-9 resulted in reduced potency, narrower effective concentration range and/or decreased efficacy. Removal of the N-terminal serine or the COOH-terminal isoleucine-proline-alanine from ADNF-9 produced a significant reduction in survival-promoting activity. Comparative studies of ADNF-9 action in mixed (glia plus neurons) vs. glia-depleted neuronal cultures indicated that ADNF-9 can act directly on neurons, although the potency of the peptide was 10,000-fold greater in mixed cultures. Kinetic studies showed that exposure to ADNF-9 for only 2 hr was sufficient to produce a 4-day protection against the cell-killing action of tetrodotoxin. Treatment with bafilomycin A1 (an inhibitor of receptor-mediated endocytosis) for 2 hr prevented the ADNF- and ADNF-9-mediated neuroprotection. ADNF-9, like ADNF-14, was neuroprotective against N-methyl-D-aspartate and the beta-amyloid peptide (amino acids 25-35), and had a much broader range of effective concentrations than ADNF-14. These studies identify ADNF-9 as an attractive lead compound for the development of therapeutic agents against neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580606

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  36 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

2.  A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta.

Authors:  Y Hashimoto; T Niikura; H Tajima; T Yasukawa; H Sudo; Y Ito; Y Kita; M Kawasumi; K Kouyama; M Doyu; G Sobue; T Koide; S Tsuji; J Lang; K Kurokawa; I Nishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

3.  Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures.

Authors:  Virginia L Smith-Swintosky; Illana Gozes; Douglas E Brenneman; Michael R D'Andrea; Carlos R Plata-Salaman
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

5.  Activity-dependent neuroprotective protein-derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse.

Authors:  Y Sari
Journal:  Neuroscience       Date:  2008-11-21       Impact factor: 3.590

6.  Peptidergic agonists of activity-dependent neurotrophic factor protect against prenatal alcohol-induced neural tube defects and serotonin neuron loss.

Authors:  Feng C Zhou; Yuan Fang; Charles Goodlett
Journal:  Alcohol Clin Exp Res       Date:  2008-06-28       Impact factor: 3.455

7.  Neurotrophic peptides, ADNF-9 and NAP, prevent alcohol-induced apoptosis at midgestation in fetal brains of C57BL/6 mouse.

Authors:  Youssef Sari; Jason M Weedman; Maxwell Nkrumah-Abrokwah
Journal:  J Mol Neurosci       Date:  2012-11-16       Impact factor: 3.444

8.  Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.

Authors:  G Yacila; Y Sari
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

9.  Structure analysis of activity-dependent neurotrophic factor 9 by circular dichroism and sedimentation equilibrium.

Authors:  Tsutomu Arakawa; Takako Niikura; Hirohisa Tajima; Fumio Arisaka; Yoshiko Kita
Journal:  J Mol Neurosci       Date:  2007-05-31       Impact factor: 3.444

10.  NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).

Authors:  Illana Gozes; Inna Divinski; Inbar Piltzer
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.